The Coherex WaveCrest is the latest development in left atrial appendage occlusion.
The WaveCrest device is uniquely designed to improve confidence in clinical outcomes through:
- Control of placement with retractable anchors
- Visualization of acute closure, position, and stability
- Rapid endothelization
Coherex has received CE Mark approval for the WaveCrest and expects to begin commercialization outside the US immediately.
Plans are underway to conduct clinical trials leading to regulatory approval in the USA and Japan.
The WaveCrest LAA Occluder is an implantable device that seals off the LAA opening so clots cannot escape into the blood stream and cause a stroke. It is a one-time treatment option for patients who would otherwise be on a lifetime regimen of anticoagulation therapy.